As part of NSF International’s global health science consulting business, CRO will be known as Amarex Clinical Research, an NSF International Company
NSF International has acquired a majority interest in Amarex Clinical Research, a clinical stage contract research organisation (CRO) headquartered in Germantown, Maryland. As part of NSF International’s global health science consulting business, the highly-respected CRO will be known as Amarex Clinical Research, an NSF International Company.
Amarex Clinical Research, will gain access to NSF International’s expert network and international scope. As part of NSF’s global network of locations, Amarex will continue to operate from its US office near Washington, DC. The company also operates an office in Taiwan and has a developing presence in Europe.
Commenting on the deal, Kevan Lawlor, President and CEO, NSF International said,“Amarex brings clinical trial expertise to NSF International’s large base of training, quality and consulting clients, and Amarex’s CRO clients may now benefit from NSF International’s global reach and expertise in European Union Qualified Person and Medical Device Regulation training, chemistry manufacturing and controls support, and supplement testing inspection and certification.”
“Amarex will be able to leverage NSF International’s global infrastructure to expand our contract research capabilities and better serve clients with the design and execution of clinical trials and navigating the FDA, TFDA and EMA regulatory approval process,” said Dr Kazem Kazempour, Founder, Amarex who will continue as President and CEO of Amarex, an NSF International company.
As part of NSF International, Amarex will support companies with regulatory affairs, project/trial management, clinical operations, biostatistics, data management, pharmacovigilance, data monitoring committees, medical writing and consulting.
- Advertisement -